Real-world associations between outcomes and biomarkers in severe asthma patients treated with biologics

John Townend; TRUNG N TRAN; Neil  Martin; Andrew N Menzies-Gow; Eileen Wang; Michael E Wechsler; G Walter Canonica; Enrico Heffler; Luis Perez de Llano; Borja G. Cosio; Mark Hew; Matthew Peters; Peter Gerard Gibson; Sinthia  Bosnic-Anticevitch; Liam G Heaney; David J Jackson; Paul E Pfeffer; John Busby; Sundeep Salvi; George C.  Christoff; Todor A Popov; Celeste M. Porsbjerg; Carlos A.  Torres-Duque; Riyad  Al-Lehebi; Mona Al-Ahmad; Diahn Warng Perng; Celine Bergeron; Mohsen Sadatsafavi; Bassam Mahboub; Takashi Iwanaga; Jorge F Maspero; Piotr Kuna; Chin Kook Rhee; Desiree Larenas-Linnemann; Nikolaos G Papadopoulos; Andriana L. Papaioannou; Joao A Fonseca; Mariko Siyue Koh; Richard W  Costello; David Price

doi:10.1183/13993003.congress-2023.PA1897

Real-world associations between outcomes and biomarkers in severe asthma patients treated with biologics

John Townend, TRUNG N TRAN, Neil Martin, Andrew N Menzies-Gow, Eileen Wang, Michael E Wechsler, G Walter Canonica, Enrico Heffler, Luis Perez de Llano, Borja G. Cosio, Mark Hew, Matthew Peters, Peter Gerard Gibson, Sinthia Bosnic-Anticevitch, Liam G Heaney, David J Jackson, Paul E Pfeffer, John Busby, Sundeep Salvi, George C. ChristoffTodor A Popov, Celeste M. Porsbjerg, Carlos A. Torres-Duque, Riyad Al-Lehebi, Mona Al-Ahmad, Diahn Warng Perng, Celine Bergeron , Mohsen Sadatsafavi, Bassam Mahboub, Takashi Iwanaga, Jorge F Maspero, Piotr Kuna, Chin Kook Rhee, Desiree Larenas-Linnemann, Nikolaos G Papadopoulos, Andriana L. Papaioannou, Joao A Fonseca, Mariko Siyue Koh, Richard W Costello, David Price

Research output: Contribution to journal › Abstract › peer-review

Abstract

Introduction
Clinical trial evidence shows that biologic efficacy for severe asthma is related to biomarkers, but the extent to which this can be used to select treatments in the real-world is unclear.
Aims and objectives
We aimed to determine if pre-biologic measurements of biomarkers were predictive of lung function and asthma control in severe asthma patients treated with anti-IL5/5R or anti-IgE biologics in realworld settings.
Methods
The International Severe Asthma Registry collects data from 23 countries. We included all patients aged ≥18 years with data on blood eosinophil count (BEC), fractional exhaled nitric oxide (FeNO) or serum immunoglobulin-E (IgE) and with pre- and post-biologic FEV1 and asthma control.
Associations between outcomes one year after biologic initiation and highest pre-biologic biomarker levels were examined using regression models, adjusting for baseline measurement of the relevant outcome.
Results
Higher baseline BEC and FeNO were associated with greater post-treatment FEV1 improvement in anti-IgE and anti-IL5/5R patients, and reduced odds of uncontrolled asthma in anti-IL5/5R patients (Figure). IgE level was not associated with either of these outcomes. A combination of BEC and FeNO
predicted follow-up FEV1 improvement more accurately than either alone (pConclusions The results support the use of BEC and FeNO to help to identify patients who will benefit most from biologics.

Original language	English
Article number	PA1897
Journal	European Respiratory Journal
Volume	62
Issue number	Suppl. 67
Early online date	9 Sept 2023
DOIs	https://doi.org/10.1183/13993003.congress-2023.PA1897
Publication status	Published - 9 Sept 2023

Access to Document

10.1183/13993003.congress-2023.PA1897Licence: Unspecified

Cite this

Townend, J., N TRAN, TRUNG., Martin, N., Menzies-Gow, A. N., Wang, E., Wechsler, M. E., Walter Canonica, G., Heffler, E., Llano, L. P. D., Cosio, B. G., Hew, M., Peters, M., Gibson, P. G., Bosnic-Anticevitch, S., Heaney, L. G., Jackson, D. J., Pfeffer, P. E., Busby, J., Salvi, S., ... Price, D. (2023). Real-world associations between outcomes and biomarkers in severe asthma patients treated with biologics. European Respiratory Journal, 62(Suppl. 67), Article PA1897. https://doi.org/10.1183/13993003.congress-2023.PA1897

Townend, J, N TRAN, TRUNG, Martin, N, Menzies-Gow, AN, Wang, E, Wechsler, ME, Walter Canonica, G, Heffler, E, Llano, LPD, Cosio, BG, Hew, M, Peters, M, Gibson, PG, Bosnic-Anticevitch, S, Heaney, LG, Jackson, DJ, Pfeffer, PE, Busby, J, Salvi, S, Christoff, GC, Popov, TA, Porsbjerg, CM, Torres-Duque, CA, Al-Lehebi, R, Al-Ahmad, M, Perng, DW, Bergeron , C, Sadatsafavi, M, Mahboub, B, Iwanaga, T, Maspero, JF, Kuna, P, Rhee, CK, Larenas-Linnemann, D, Papadopoulos, NG, Papaioannou, AL, Fonseca, JA, Koh, MS, Costello, RW & Price, D 2023, 'Real-world associations between outcomes and biomarkers in severe asthma patients treated with biologics', European Respiratory Journal, vol. 62, no. Suppl. 67, PA1897. https://doi.org/10.1183/13993003.congress-2023.PA1897

@article{bbcac4799c144d9a9967c773613a1fa6,

title = "Real-world associations between outcomes and biomarkers in severe asthma patients treated with biologics",

abstract = "IntroductionClinical trial evidence shows that biologic efficacy for severe asthma is related to biomarkers, but the extent to which this can be used to select treatments in the real-world is unclear.Aims and objectivesWe aimed to determine if pre-biologic measurements of biomarkers were predictive of lung function and asthma control in severe asthma patients treated with anti-IL5/5R or anti-IgE biologics in realworld settings.MethodsThe International Severe Asthma Registry collects data from 23 countries. We included all patients aged ≥18 years with data on blood eosinophil count (BEC), fractional exhaled nitric oxide (FeNO) or serum immunoglobulin-E (IgE) and with pre- and post-biologic FEV1 and asthma control.Associations between outcomes one year after biologic initiation and highest pre-biologic biomarker levels were examined using regression models, adjusting for baseline measurement of the relevant outcome.ResultsHigher baseline BEC and FeNO were associated with greater post-treatment FEV1 improvement in anti-IgE and anti-IL5/5R patients, and reduced odds of uncontrolled asthma in anti-IL5/5R patients (Figure). IgE level was not associated with either of these outcomes. A combination of BEC and FeNO predicted follow-up FEV1 improvement more accurately than either alone (pConclusions The results support the use of BEC and FeNO to help to identify patients who will benefit most from biologics.",

author = "John Townend and {N TRAN}, TRUNG and Neil Martin and Menzies-Gow, {Andrew N} and Eileen Wang and Wechsler, {Michael E} and {Walter Canonica}, G and Enrico Heffler and Llano, {Luis Perez de} and Cosio, {Borja G.} and Mark Hew and Matthew Peters and Gibson, {Peter Gerard} and Sinthia Bosnic-Anticevitch and Heaney, {Liam G} and Jackson, {David J} and Pfeffer, {Paul E} and John Busby and Sundeep Salvi and Christoff, {George C.} and Popov, {Todor A} and Porsbjerg, {Celeste M.} and Torres-Duque, {Carlos A.} and Riyad Al-Lehebi and Mona Al-Ahmad and Perng, {Diahn Warng} and Celine Bergeron and Mohsen Sadatsafavi and Bassam Mahboub and Takashi Iwanaga and Maspero, {Jorge F} and Piotr Kuna and Rhee, {Chin Kook} and Desiree Larenas-Linnemann and Papadopoulos, {Nikolaos G} and Papaioannou, {Andriana L.} and Fonseca, {Joao A} and Koh, {Mariko Siyue} and Costello, {Richard W} and David Price",

year = "2023",

month = sep,

day = "9",

doi = "10.1183/13993003.congress-2023.PA1897",

language = "English",

volume = "62",

journal = "European Respiratory Journal",

issn = "0903-1936",

publisher = "European Respiratory Society",

number = "Suppl. 67",

}

TY - JOUR

T1 - Real-world associations between outcomes and biomarkers in severe asthma patients treated with biologics

AU - Townend, John

AU - N TRAN, TRUNG

AU - Martin, Neil

AU - Menzies-Gow, Andrew N

AU - Wang, Eileen

AU - Wechsler, Michael E

AU - Walter Canonica, G

AU - Heffler, Enrico

AU - Llano, Luis Perez de

AU - Cosio, Borja G.

AU - Hew, Mark

AU - Peters, Matthew

AU - Gibson, Peter Gerard

AU - Bosnic-Anticevitch, Sinthia

AU - Heaney, Liam G

AU - Jackson, David J

AU - Pfeffer, Paul E

AU - Busby, John

AU - Salvi, Sundeep

AU - Christoff, George C.

AU - Popov, Todor A

AU - Porsbjerg, Celeste M.

AU - Torres-Duque, Carlos A.

AU - Al-Lehebi, Riyad

AU - Al-Ahmad, Mona

AU - Perng, Diahn Warng

AU - Bergeron , Celine

AU - Sadatsafavi, Mohsen

AU - Mahboub, Bassam

AU - Iwanaga, Takashi

AU - Maspero, Jorge F

AU - Kuna, Piotr

AU - Rhee, Chin Kook

AU - Larenas-Linnemann, Desiree

AU - Papadopoulos, Nikolaos G

AU - Papaioannou, Andriana L.

AU - Fonseca, Joao A

AU - Koh, Mariko Siyue

AU - Costello, Richard W

AU - Price, David

PY - 2023/9/9

Y1 - 2023/9/9

N2 - IntroductionClinical trial evidence shows that biologic efficacy for severe asthma is related to biomarkers, but the extent to which this can be used to select treatments in the real-world is unclear.Aims and objectivesWe aimed to determine if pre-biologic measurements of biomarkers were predictive of lung function and asthma control in severe asthma patients treated with anti-IL5/5R or anti-IgE biologics in realworld settings.MethodsThe International Severe Asthma Registry collects data from 23 countries. We included all patients aged ≥18 years with data on blood eosinophil count (BEC), fractional exhaled nitric oxide (FeNO) or serum immunoglobulin-E (IgE) and with pre- and post-biologic FEV1 and asthma control.Associations between outcomes one year after biologic initiation and highest pre-biologic biomarker levels were examined using regression models, adjusting for baseline measurement of the relevant outcome.ResultsHigher baseline BEC and FeNO were associated with greater post-treatment FEV1 improvement in anti-IgE and anti-IL5/5R patients, and reduced odds of uncontrolled asthma in anti-IL5/5R patients (Figure). IgE level was not associated with either of these outcomes. A combination of BEC and FeNO predicted follow-up FEV1 improvement more accurately than either alone (pConclusions The results support the use of BEC and FeNO to help to identify patients who will benefit most from biologics.

AB - IntroductionClinical trial evidence shows that biologic efficacy for severe asthma is related to biomarkers, but the extent to which this can be used to select treatments in the real-world is unclear.Aims and objectivesWe aimed to determine if pre-biologic measurements of biomarkers were predictive of lung function and asthma control in severe asthma patients treated with anti-IL5/5R or anti-IgE biologics in realworld settings.MethodsThe International Severe Asthma Registry collects data from 23 countries. We included all patients aged ≥18 years with data on blood eosinophil count (BEC), fractional exhaled nitric oxide (FeNO) or serum immunoglobulin-E (IgE) and with pre- and post-biologic FEV1 and asthma control.Associations between outcomes one year after biologic initiation and highest pre-biologic biomarker levels were examined using regression models, adjusting for baseline measurement of the relevant outcome.ResultsHigher baseline BEC and FeNO were associated with greater post-treatment FEV1 improvement in anti-IgE and anti-IL5/5R patients, and reduced odds of uncontrolled asthma in anti-IL5/5R patients (Figure). IgE level was not associated with either of these outcomes. A combination of BEC and FeNO predicted follow-up FEV1 improvement more accurately than either alone (pConclusions The results support the use of BEC and FeNO to help to identify patients who will benefit most from biologics.

UR - https://k4.ersnet.org/prod/v2/front/program/?e=379

U2 - 10.1183/13993003.congress-2023.PA1897

DO - 10.1183/13993003.congress-2023.PA1897

M3 - Abstract

SN - 0903-1936

VL - 62

JO - European Respiratory Journal

JF - European Respiratory Journal

IS - Suppl. 67

M1 - PA1897

ER -

Real-world associations between outcomes and biomarkers in severe asthma patients treated with biologics

Abstract

Access to Document

Other files and links

Fingerprint

Cite this